前列地尔联合替比夫定对乙肝肝硬化患者疗效和血清炎性因子的影响

doi:10.3969/j.issn.1006-6233.2017.12.008

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1385 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的:探讨替前列地尔联合替比夫定对乙肝肝硬化患者临床效果及血清炎性因子的影响,为临床治疗提供理论依据。方法:选取本院消化内科2014年6月至2016年6月就诊的乙肝肝硬化患者98例,按随机数字表分为替比夫定组(49例)和联合组(49例)。在常规治疗的基础上,替比夫定组给予替比夫定,联合组在替比夫定的基础上给予前列地尔,治疗12周。观察两组患者治疗前后血清HBV DNA水平、肝功能及血清炎性因子的变化情况。结果:治疗后,联合组患者临床有效率高于替比夫定组(89.30%VS.63.89%,P<0.05),两组患者血清HBV DNA水平较治疗前降低(P<0.05),但是治疗后两组间差异未见统计学意义(P>0.05)。治疗后,两组患者血清AST、ALT、Tbil、IL-6、IL-22、hs-CRP的水平低于治疗前,而且联合组血清AST、ALT、Tbil、IL-6、IL-22、hs-CRP的水平明显低于替比夫定组(P<0.05)。结论:前列地尔联合替比夫定可以降低乙肝肝硬化患者血清HBV DNA的水平,改善患者肝功能和缓解炎症反应,具有良好临床疗效。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	陈逊
	刘海滨

关键词 ：前列地尔, 替比夫定, 乙型肝炎肝硬化, 炎性因子

Abstract：Objective: To explore clinical efficacy and serum inflammatory factor use of alprostadil combined with telbivudine in treatment of hepatitis B virus-related cirrhosis,providing a theoretical basis for clinical treatment. Methods:98 patients with hepatitis B cirrhosis admitted in our hospital from June 2014 to June 2016, were selected. According to the random number table, patients were divided into telbivudine group (49 cases) and combined group (49 cases). On the basis of routine treatment, telbivudine group was given telbivudine, combined group was given telbivudine and alprostadil for 12 weeks. To observe and analyze the changes of serum HBV DNA levels, liver function and serum inflammatory factor. Results:After treatment, overall efficacy of combined group was significantly higher than that of telbivudine group (89.30% VS.63.89%,P< 0.05).After treatment, the serum HBV and DNA levels of the two groups were significant lower than those before treatment,but there was no significant difference (P>0.05) between two groups. After treatment, serum AST, ALT, Tbil, IL-6, IL-22 and hs-CRP levels of combined group were significantly lower than those of telbivudine group (P<0.05). Conclusion:Alprostadil combined with telbivudine could reduce serum HBV DNA levels, improve liver function, and alleviate the inflammatory condition of patients with ghepatitis B virus-related cirrhosis.

Key words： Alprostadil Telbivudine Hepatitis B virus-related cirrhosis Inflammatory factor

引用本文:

陈逊,刘海滨. 前列地尔联合替比夫定对乙肝肝硬化患者疗效和血清炎性因子的影响[J]. 河北医学, 2017, 23(12): 1963-1965.
CHEN Xun, LIU Haibin. Effects of Alprostadil Combined with Telbivudine on Clinical Efficacy and Serum Inflammatory Factor in Patients of Hepatitis B Virus-related Cirrhosis. HeBei Med, 2017, 23(12): 1963-1965.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2017.12.008 或 http://www.hbyxzzs.cn/CN/Y2017/V23/I12/1963

[1] 康瑜,陈建芳,曾甜.慢性乙型肝炎肝硬化患者Th22细胞和IL-22的表达及意义[J].免疫学杂志,2017,33(2):147~151.
[2] 雷子庆,张鑫.替诺福韦和恩替卡韦治疗乙型肝炎肝硬化的疗效对比[J].分子影像学杂志,2016,39(4):383~386.
[3] Huang SS, Xie DM, Cai YJ, et al. C-reactive protein-to-albumin ratio is a predictor of hepatitis B virus related decompensated cirrhosis: time-dependent receiver operating characteristics and decision curve analysis[J].Eur Gastroenterol Hepatol,2017,29(4):472~480.
[4] 赵红霞,周建华,张宏宇.慢性乙肝患者血清大蛋白表达及其与Th1/Th2细胞因子水平的关系[J].山东医药,2014,54(26):43~45.
[5] 刘浩.前列地尔联合替米沙坦治疗糖尿病肾病疗效观察[J].蚌埠医学院学报,2016,41(7):861~862,865.
[6] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防冶指南(2010年版)[J].中华肝脏病杂志,2011,19(1):13~14.
[7] 吴松柏,暴宏伶,艾素玲,等.益气解毒软肝汤治疗乙型肝炎后肝硬化38例[J].中国实验方剂学杂志,2013,19(21):285~289.
[8] 李国焕,舒盼,张均倡,等.恩替卡韦联合扶正化瘀胶囊治疗乙型肝炎肝硬化疗效观察[J].实用肝脏病杂志,2015,18(6):616~619.
[9] 李广明,赵小丽,胡善雷,等.替比夫定治疗慢性乙型肝炎病毒感染孕妇的安全性及有效性评价[J].中华医院感染学杂志,2014,24(9):2169~2171.
[10] 王忠琼,刘翼,夏国栋,等.前列地尔对乙肝肝硬化患者血清炎性因子及肝功能的影响[J].医学研究生学报,2017,30(6):611~614.
[11] 李慧丽,卢雪峰,李娜.恩替卡韦联合前列地尔治疗乙型肝炎肝硬化腹水的效果观察[J].临床肝胆病杂志,2016,32(2):292~295.
[12] 郑建敏.替比夫定与前列地尔联和治疗慢性乙型肝炎肝硬化的临床疗效观察[J].现代实用医学,2014,26(6):722~724.
[13] 周全,李海霞,王丽,等.疏肝健脾汤对早期乙肝肝硬化患者血清炎性因子的影响[J].中药材,2017,40(4):961~963.